20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Rapport Therapeutics, Inc. Common Stock (RAPP) operates in the BIOTECHNOLOGY industry and is headquartered in Boston, United States with about 84 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, RAPP reported $0M in revenue and ($111M) in net income.
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders.
Interactive charts & full statements → Open the RAPP valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $20M | $0M | $0M | $0M | — |
| Gross Profit | — | ($1M) | ($1M) | $0M | $0M |
| Gross Margin % | — | — | — | — | — |
| Operating Income (EBIT) | ($154M) | ($125M) | ($83M) | ($36M) | ($10M) |
| Operating Margin % | -767.6% | — | — | — | — |
| Net Income | ($137M) | ($111M) | ($78M) | ($35M) | ($11M) |
| Net Margin % | -685.8% | — | — | — | — |
| EBITDA | ($148M) | ($124M) | ($82M) | ($36M) | ($10M) |
| Earnings Per Share (EPS) | $-3.04 | $-2.37 | $-3.78 | $-1.92 | $-0.53 |
| Shares Outstanding (M) | 47M | 47M | 21M | 18M | 20M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $20M | $0M | $0M | $0M | $0M | $1M | $0M |
| Gross Profit | — | $20M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Margin % | — | 100.0% | — | — | — | — | -36.1% | — |
| Operating Income (EBIT) | ($61M) | ($24M) | ($39M) | ($30M) | ($29M) | ($27M) | ($24M) | ($22M) |
| Operating Margin % | — | -121.1% | — | — | — | — | -3266.8% | — |
| Net Income | ($57M) | ($20M) | ($34M) | ($27M) | ($27M) | ($24M) | ($20M) | ($18M) |
| Net Margin % | — | -99.3% | — | — | — | — | -2775.0% | — |
| EBITDA | ($56M) | ($24M) | ($38M) | ($30M) | ($29M) | ($27M) | ($23M) | ($21M) |
| Earnings Per Share (EPS) | $-1.19 | $-0.42 | $-0.72 | $-0.71 | $-0.75 | $-1.25 | $-1.04 | $-0.91 |
| Shares Outstanding (M) | 47M | 47M | 47M | 38M | 35M | 19M | 19M | 19M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($97M) | ($87M) | ($65M) | ($27M) | ($3M) |
| Capital Expenditures (CapEx) | $0M | $1M | $2M | $2M | $0M |
| Free Cash Flow (FCF) | ($97M) | ($88M) | ($67M) | ($29M) | ($4M) |
| FCF Margin % | -485.8% | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($41M) | ($13M) | ($25M) | ($17M) | ($25M) | ($20M) | ($14M) | ($16M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($42M) | ($13M) | ($25M) | ($18M) | ($25M) | ($21M) | ($15M) | ($17M) |
| FCF Margin % | — | -65.7% | — | — | — | — | -2037.8% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets | $459M | $512M | $315M | $155M | $32M |
| Cash & Cash Equivalents | $64M | $53M | $57M | $70M | $31M |
| Total Liabilities | $36M | $28M | $10M | $181M | $12M |
| Total Debt (Short + Long-Term) | $2M | $3M | $1M | $1M | $0M |
| Total Shareholders' Equity | $423M | $485M | $305M | ($26M) | $20M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive RAPP viewer.
About TickerBase · Data methodology & sources · Privacy · Terms